We suggest you to use Biota Pharmaceuticals analysis to find out if markets are presently mispricing the company. We found thirty available fundamental indicators for Biota Pharmaceuticals Inc which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Biota Pharmaceuticals fundamentals including its Price to Sales, Gross Profit and the relationship between Price to Book and Revenue .
Biota competes with BHP BILLITON, CWTH, RIO TINTO, WESTPAC, and ANZ BANKING. It offers zanamivir a neuraminidase inhibitor for the treatment and prophylaxis of influenza and laninamivir for the treatment of influenza. Biota Holdings Ltd. also offer influenza diagnostics test kits such as BioStar OIA FLU which detects influenza and assists the physician to differentiate influenza from other respiratory infections that may display similar symptoms and Biostar OIA FLU AB a flu test that distinguishes between influenza A and B. In addition it discovers develops and commercializes antiinfective solutions for the treatment of influenza respiratory syncytial virus human rhinovirus and hepatitis C and new classes of antibiotics to treat hospitalacquired and communityassociated infections. Biota Holdings Ltd. has a coownership agreement with Daiichi Sankyo to manufacture and sell second generation inhaled antivirals in Japan and a licensing agreement with GlaxoSmithKline to manufacture market and sell zanamivir worldwide. Biota Holdings Limited was incorporated in 1985 and is based in Notting Hill Australia.
Biota Pharmaceuticals Inc has less than 39.6 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide.
Please fill out our quick survey to help us provide your with a better service and user experience
Most of the functionality on our site is free to use.
However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented
capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory